Pharmaceuticals company Sun Pharmaceutical Industries announced Q1FY26 results Gross sales at Rs 1,37,861 million, growth of 10.1%. India formulation sales at Rs 47,211 million, up 13.9%. US formulation sales at USD 473 million, up 1.4%. Global Innovative Medicines sales at USD 311 million, up 16.9%, accounting for 19.3% of Q1FY26 sales. Emerging Markets formulation sales at USD 298 million, up 5.1%. Rest of World formulation sales at USD 219 million, up 15.5%. R&D; investments at Rs 9,029 million or 6.5% of sales compared to Rs 7,940 million for Q1FY25. EBITDA at Rs 43,017 million (including other operating revenues), up 19.2%, with resulting EBITDA margin of 31.1%. Profit before exceptional items and tax was Rs 39,908 million up 16.6%. Adjusted net profit (excluding the exceptional items) for Q1FY26 was Rs 29,961 million, up 5.7%. Reported net profit for Q1FY26 was Rs 22,786 million compared to Rs 28,356 million during Q1FY25. Dilip Shanghvi, Chairman and Managing Director, said: "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business." Result PDF